retatrutide eli lilly press release 2024 2025 Exec Talks New Weight Loss Pill, Trial Progress Lilly's triple agonist delivers up
Description
Medical research is advancing towards more personalised medical strategies, with growing acknowledgement that responses by patients to GLP-1 receptor agonists might differ markedly
, ,
Koch CA, Uwaifo GI
Best Pract Res Clin Gastroenterol 24:167182
It addresses one of its primary biological drivers
These insights help your provider determine whether semaglutide or tirzepatide will be most effective for your specific genetic profile, optimizing your treatment plan
